<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>a2106678zex-10_9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<div style="font-family:'Times New Roman';">

<p align="right" style="font-weight:bold;margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit
10.9</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOTE: <b><font style="font-weight:bold;">Portions
of this Exhibit are the subject of a Confidential Treatment Request by the
Registrant to the Securities and Exchange Commission. Such portions have been
redacted and are marked with a &quot;[*]&quot; in place of the redacted
language.</font></b></font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECOND AMENDMENT TO</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">LICENSE AGREEMENT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><font size="2" style="font-size:10.0pt;">This is the
Second Amendment to the License Agreement (the &#147;Agreement&#148;) between Sangamo
BioSciences, Inc. (&#147;Sangamo&#148;) and Baxter Healthcare Corporation (&#147;Baxter&#148;),
dated January 11, 2000.&#160; This Second
Amendment shall be effective as of November 14, 2002.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">RECITALS</font></b></h1>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; WHEREAS</font></b><font size="2" style="font-size:10.0pt;">, the Agreement
was assigned by Baxter to Edwards Lifesciences LLC (&#147;Edwards&#148;) pursuant to a
Reorganization Agreement between Baxter International Inc. and Edwards
Lifesciences Corporation dated March 31, 2000; and</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><font style="font-weight:bold;">WHEREAS</font></b>,
a First Amendment to the License Agreement (&#147;First Amendment&#148;) was entered into
by Sangamo and Edwards effective October 16, 2001.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><font style="font-weight:bold;">NOW,
THEREFORE, </font></b>for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Agreement is hereby amended as
follows:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Every occurrence
of &#147;Baxter Healthcare Corporation&#148; in the Agreement shall be replaced with
&#147;Edwards Lifesciences LLC&#148; and every occurrence of &#147;Baxter&#148; shall be replaced
with &#147;Edwards&#148;.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Delete
Section 4.2&#160; Convertible Debenture and
Milestone Payments, and delete paragraphs 4.2.1(b)(i-a) and 4.2.1(b)(i) from
the First Amendment to the License Agreement.&#160;
Insert the following new Section 4.2:</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=1,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=78135,FOLIO='',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:12.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Convertible
Debenture and Milestone Payments</font></b></p>

<h2 style="font-style:italic;margin:0in 0in .0001pt .5in;page-break-after:avoid;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></i></b></h2>

<h4 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4.2.1&#160; On or before January&nbsp;21, 2000, EDWARDS
shall pay to SANGAMO the sum of Five Million Dollars ($5,000,000) in
consideration for the purchase of a Convertible Debenture having a face amount
of Five Million Dollars ($5,000,000).</font></h4>

<h4 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4.2.2&#160; Within thirty (30) days of the first
achievement of each of the following research and development milestones,
EDWARDS shall pay to SANGAMO the following milestone payments:</font></h4>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">(a)&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; One
million four hundred thousand dollars ($1,400,000) upon delivery to EDWARDS by
SANGAMO of data satisfactory to both Parties demonstrating the development of a
lead ZFP therapeutic product candidate and supporting pre-clinical data in a
therapeutically-relevant angiogenesis animal model;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (b)<b><font style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; *** </font></b>upon completion and
delivery of the items specified in Paragraph 5.1(b) as more specifically set
out in Amended Schedule 2 attached hereto, <b><font style="font-weight:bold;">***</font></b>;</font></p>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; *** upon completion and delivery of
the items specified in Schedule 3 attached hereto.</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:normal;">4.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; In consideration for the license rights acquired under this
Agreement, within thirty (30) days of the first achievement of each of the
following events or the respective date described, EDWARDS shall pay to SANGAMO
the following milestone payments:</font></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt .5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b><font style="font-weight:bold;">*** </font></b>upon the date of submission of the first
IND for a Licensed Product;</font></h5>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>


<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=2,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=342365,FOLIO='2',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:12.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h4 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to each Subsequent
Licensed Product, within thirty (30) days of achievement of each of the
following events or the respective date described, EDWARDS shall pay to SANGAMO
the following milestone payments:</font></h4>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (i)
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h5 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></h5>

<h3 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4.2.4&#160; ***</font></h3>

<h3 align="left" style="font-weight:normal;line-height:normal;margin:0in 0in 12.0pt .5in;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4.2.5&#160; In the event that EDWARDS must license from
a Third Party one or more pending patent applications or issued patents in
order to manufacture, have manufactured, import, use, sell and offer for sale a
Licensed Product in any country for use in the Field, EDWARDS shall have the
right to credit all up-front license payments and milestone payments actually
paid to such Third Party against up to *** owing to SANGAMO under
Clause&nbsp;4.2.1(b)(iv), (v) and (vi) and Clause&nbsp;4.2.1(c) with respect to
such Licensed Product.&#160; If the parties
disagree whether or not a pending patent application or issued patent is
consistent with the requirement set forth in this Clause&nbsp;4.2.3, the
disagreement shall be resolved pursuant to Clause&nbsp;12.</font></h3>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>


<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=3,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=443614,FOLIO='3',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:12.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;  The calendar dates described in
Clauses&nbsp;4.2.1(b)(i), (ii), (iii) and (iv) will be subject to review, and
revision if appropriate, by the Steering Committee as follows.&#160; The Steering Committee shall determine the
appropriateness of such calendar dates for the achievement of the applicable
milestone events in light of the technical and commercial feasibility of the
particular ZFP molecule being pursued at the time, and if appropriate, shall
adjust such calendar dates as agreed by the Steering Committee.</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Add the following new paragraph
3.1(i):</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In consideration for the payment by
Edwards to Sangamo of <b><font style="font-weight:bold;">***</font></b> on or before November 30, 2002, Sangamo
shall grant Edwards an exclusive option to acquire an exclusive
royalty-bearing, worldwide license to manufacture, have manufactured, import,
use, sell and offer for sale zinc finger DNA binding proteins and nucleic acids
that encode zinc finger DNA binding proteins for regulation of phospholamban
for the treatment and prevention of congestive heart failure (&#147;PLN&#148;).&#160; Edwards shall have the right to exercise
such option at any time prior to one month after completion of the PLN
milestone set forth in paragraph 4.2.2(c) or March 31, 2004, whichever is
later, by giving Sangamo written notice of its decision to exercise such
option.&#160;&#160; Thereafter, the parties shall
negotiate in good faith the terms and conditions of such a license.&#160; Should Edwards and Sangamo fail to reach an
agreement on the terms of such license within the period ending on June 30,
2004, Sangamo shall be free to license PLN to third parties.&#160; If Edwards does not exercise its option on
or before March 31, 2004, Edwards shall continue to have a right of first
refusal to PLN during the three month period ending June 30, 2004, and during
such period, Sangamo shall not enter into a license with any third party
without first giving Edwards an opportunity to acquire such license under the
same terms and conditions as those offered to such third party.&#160; After June 30, 2004, Sangamo shall be free
to license PLN to third parties.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>


<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=4,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=904550,FOLIO='4',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:12.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Delete
Paragraph 5.1(b) and insert the following new Paragraph 5.1(b):</font></p>

<p style="margin:0in 0in .0001pt .5in;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To complete and deliver to
EDWARDS the items described on Amended Schedule 2 attached hereto, and ***.</font></p>

<p style="margin:12.0pt 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ***</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The parties agree that this Second Amendment *** payment
of milestones and obligations to be performed under this Agreement.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Agreement, as amended in the First Amendment thereto
and in this Second Amendment, together with the Research Funding Agreement
between SANGAMO and EDWARDS dated January 11, 2000, as amended in the First
Amendment thereto, represent the entire agreement between the parties with respect
to its subject matter and supersede all prior agreements and understandings
between the parties.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All other terms and conditions shall remain the same.</font></p>

<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="40%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:40.04%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EDWARDS LIFESCIENCES LLC</font></b></p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="39%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:39.98%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SANGAMO BIOSCIENCES, INC.</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="40%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:40.04%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="39%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:39.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="40%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:40.04%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="39%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:39.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="40%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:40.04%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ JOHN KEHL</font></p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="39%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:39.98%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ EDWARD LANPHIER</font></p>
  </td>
 </tr>
 <tr>
  <td width="40%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:40.04%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="39%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:39.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.64%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">John Kehl</font></p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.46%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Edward Lanphier</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.64%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.4%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.52%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.46%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.64%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Vice President</font></p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.46%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President &amp; CEO</font></p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.64%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.4%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.52%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.46%;">
  <p style="font-size:12.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.64%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November 15, 2002</font></p>
  </td>
  <td width="19%" valign="bottom" style="padding:0in 0in 0in 0in;width:19.98%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>
  </td>
  <td width="34%" valign="bottom" style="padding:0in 5.4pt 0in 5.4pt;width:34.46%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November 18, 2002</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>


<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=5,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=92085,FOLIO='5',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:12.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Amended Schedule 2 to License
Agreement</font></u></i></b></p>

<p style="font-weight:bold;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></p>

<p align="center" style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">***</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>


<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=6,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=281392,FOLIO='6',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:12.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><i><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Schedule 3 to License Agreement</font></u></i></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">***</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>


<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">***Certain information on this page has been
omitted and filed separately with the Commission pursuant to a request for
Confidential Treatment.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- ZEQ.=1,SEQ=7,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2",CHK=761548,FOLIO='7',FILE="DISK025:[03PAL2.03PAL1262.EDGAR]EX10-9_1262.CHC",USER="DROCCON",CD='Mar 27 11:07 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

</div>

<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DROCCON,SEQ=,EFW="2106678",CP="SANGAMO BIOSCIENCES, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
